Defence Therapeutics Inc.
DTC
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 73.38% | 70.20% | -58.48% | -92.56% | -83.30% |
| Total Depreciation and Amortization | 129.69% | 706.80% | 257.36% | 555.88% | 233.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -84.91% | -120.59% | 1,048.61% | 1,265.44% | 1,001.95% |
| Change in Net Operating Assets | -123.62% | 683.43% | 379.83% | 290.32% | 2,431.77% |
| Cash from Operations | 50.06% | 36.61% | 63.25% | 44.28% | 13.97% |
| Capital Expenditure | 107.43% | -1,618.82% | -174.11% | -211.13% | -272.77% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 115.39% | -1,462.35% | -174.11% | -211.13% | -272.77% |
| Total Debt Issued | -- | -- | -97.24% | -97.88% | -100.00% |
| Total Debt Repaid | -312.31% | -1,274.83% | -393.88% | -- | -633.87% |
| Issuance of Common Stock | 23.93% | -61.22% | -73.16% | -77.10% | -35.09% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -9.14% | 57.16% | 76.87% | 79.03% | 47.87% |
| Cash from Financing | 15.91% | -63.76% | -80.08% | -82.50% | -53.68% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 161.28% | -203.64% | -200.87% | -220.87% | -296.56% |